New hope for SCA patients: expanded access to investigational drug troriluzole
NCT ID NCT06034886
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This expanded access program offers the investigational drug troriluzole to people with spinocerebellar ataxia (SCA), a rare brain disorder that affects movement and coordination. Participants take a daily pill. The goal is to provide access to the drug while it is still being studied. Eligible patients must have a confirmed SCA diagnosis and adequate liver function.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- troriluzole (also known as BHV-4157), taken as a daily pill
- What this could lead to
- If it works, this could help slow or manage symptoms of spinocerebellar ataxia, a rare and progressive neurological disease.
- What could go wrong
- This is an expanded access program, not a formal trial, so evidence is limited. The drug is still investigational and may not work for everyone. Liver function must be monitored.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists decode gait signatures to spot brain diseases
- Could stem cells help people with spinocerebellar ataxia?
- Could a drug slow rare brain disease? new study uses Real-World data to find out
- New study sheds light on vision loss in rare genetic brain disorders
- Body-Worn sensors could revolutionize ataxia tracking
- New drug could slow rare brain disease that steals balance